Leveraging a deep understanding of cellular homeostasis to create life-changing medicines
ABOUT US
Crown Point-based biotech firm developing diabetes drug former Merck exec describes as potential 'gamechanger'
VIEW ARTICLE
Targeting cellular stress pathways via rational drug design to develop curative therapeutics
OUR SCIENCE
Progressing first-in-class, disease modifying small molecules into innovative treatment options
OUR PIPELINEBreakthrough Therapeutics for Intractable Diseases
Neurodon is taking a different approach by targeting stress pathways common to the most devastating diseases.
We are a development-stage pharmaceutical company that is developing disease-modifying molecules targeting neurodegeneration, diabetes, and other life-threatening conditions by deploying a proprietary ER stress-based technology platform — halting diseases and improving lives with innovative small molecule therapies.
Innovative Science
Our focus is two-fold: rigorous scientific investigation coupled with expedient clinical translation.
Neurodon’s deep understanding of pathological cellular pathways and decades of experience in drug development and clinical translation have enabled the development of medicines that show promise to treat some of the most challenging diseases of our time.
Partners and Investors
Neurodon actively collaborates with institutions on pioneering advancements to validate new therapeutic candidates with novel targets.
